lung, and other cancers in adults. For a doctor to prescribe Enhertu, the cancer must involve HER2 in some way. Each of these cancers also has other specific criteria for treatment with Enhertu ...

Enhertu already has seven FDA approvals across breast cancer, gastric cancer, non-small cell lung cancer (NSCLC), and advanced HER2-positive solid tumours, which have driven sales to more than $3. ...

Enhertu improved overall survival versus chemotherapy in HER2-positive metastatic gastric cancer, prompting an interim ...

The partners are pushing to expand Enhertu’s list of indications beyond its standing uses in breast, lung and gastric cancers ...

In the DESTINY-Breast03 trial, Enhertu (trastuzumab deruxtecan ... the DESTINY-Lung01 study in HER2-positive non-small cell lung cancer (NSCLC), including an overall response rate of 55% and ...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union (EU) as monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC) whose disease has not ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for ... A lot of times, when we get our scans, we might see subclinical interstitial ...

AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a randomized clinical trial in second-line metastatic stomach cancer ...

Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology and international markets. Core operating profit rose 33% to ¥229 billion. CFO Koji Ogawa ...

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ...

Interstitial lung disease or pneumonitis was reported in 11.3% of patients treated with ENHERTU, with most cases being low grade. Currently, ENHERTU is approved in over 75 countries for patients with ...